Last reviewed · How we verify
ONO-1101
ONO-1101 is a monoclonal antibody targeting PD-1.
ONO-1101 is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | ONO-1101 |
|---|---|
| Sponsor | Ono Pharmaceutical Co. Ltd |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ONO-1101 works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells and thereby enhancing the immune response against cancer cells.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
Key clinical trials
- Landiolol in Mitral Valve Surgery (PHASE4)
- Impact of Cardio-Selective Beta-Blockers on Infarct Size After Acute Myocardial Infarction
- LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery (PHASE4)
- Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility (PHASE3)
- Landiolol in Postoperative Atrial Fibrillation (PHASE3)
- LANdiolol MIcrocirculatory Effects During Septic chOc (MILANOS) (PHASE3)
- Prevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac Surgery (PHASE3)
- Beta-blockade With Landiolol in Out-of-hospital Cardiac Arrest (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ONO-1101 CI brief — competitive landscape report
- ONO-1101 updates RSS · CI watch RSS
- Ono Pharmaceutical Co. Ltd portfolio CI